These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 16485915)

  • 1. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
    Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
    Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
    Chapman TM; Plosker GL; Perry CM
    Drugs; 2004; 64(18):2101-24. PubMed ID: 15341507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
    Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
    Brouwers J; Tack J; Augustijns P
    Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM; Gibiansky L; Wire MB
    J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
    Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosamprenavir: advancing HIV protease inhibitor treatment options.
    Becker S; Thornton L
    Expert Opin Pharmacother; 2004 Sep; 5(9):1995-2005. PubMed ID: 15330736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
    Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Gazzard B; Pozniak A
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1376-84. PubMed ID: 15483467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology and pharmacokinetics of amprenavir.
    Sadler BM; Stein DS
    Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of darunavir.
    Rittweger M; Arastéh K
    Clin Pharmacokinet; 2007; 46(9):739-56. PubMed ID: 17713972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.